SaNOtize Research & Development Corp.: Phase 3 Clinical Trial Confirms SaNOtize's Breakthrough Treatment is 99% Effective Against COVID-19; Receives Regulatory Approval in India
Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours